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Tissue factor pathway inhibitor 2Tissue factor pathway inhibitor 2 (TFPI2) is a serine protease inhibitor critical for the regulation of
extracellular matrix remodeling and atherosclerotic plaque stability. Previously, we demonstrated that TFPI2
expression is increased in monocytes from patients with familial combined hyperlipidemia (FCH). To gain
insight into the molecular mechanisms responsible for this upregulation, we examined TFPI2 expression in
THP-1 macrophages exposed to lipoproteins and thrombin. Our results showed that TFPI2 expression was not
affected by treatment with very low density lipoproteins (VLDL), but was induced by thrombin (10 U/ml) in
THP-1 (1.9-fold increase, pb0.001) and human monocyte-derived macrophages (2.3-fold increase, pb0.005).
The speciﬁcity of the inductive effect was demonstrated by preincubation with the thrombin inhibitors
hirudin and PPACK, which ablated thrombin effects. TFPI2 induction was prevented by pre-incubation with
MEK1/2 and JNK inhibitors, but not by the EGF receptor antagonist AG1478. In the presence of parthenolide,
an inhibitor of NFκB, but not of SR-11302, a selective AP-1 inhibitor, thrombin-mediated TFPI2 induction was
blunted. Our results also show that thrombin treatment increased ERK1/2, JNK and IκBα phosphorylation.
Finally, we ruled out the possibility that TFPI2 induction by thrombin was mediated by COX-2, as
preincubation with a selective COX-2 inhibitor did not prevent the inductive effect. In conclusion, thrombin
induces TFPI2 expression by a mechanism involving ERK1/2 and JNK phosphorylation, leading ﬁnally to NFkB
activation. In the context of atherosclerosis, thrombin-induced macrophage TFPI2 expression could represent
a means of avoiding excessive activation of matrix metalloproteases at sites of inﬂammation.acultad de Farmacia e Instituto
onal 643, Barcelona E-08028,
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
TFPI2 is a Kunitz-type serine protease inhibitor expressed in smooth
muscle cells, macrophages, T cells and endothelial cells [1]. It presents a
high degree of homology to TFPI1, an important regulator of the
extrinsic pathway of blood coagulation [2]. The physiological role of
TFPI2 has yet to be established, but it has been suggested that it is critical
for the regulation of extracellular matrix (ECM) remodeling, due to its
ability to inhibit plasmin andmatrixmetalloproteinases (MMP) [3]. As a
consequence, TFPI2 is involved in pathological processes such as tumor
invasion andmetastasis dissemination [4], aswell as in the regulation of
atherosclerotic plaque stability [1]. Moreover, although TFPI2 does not
directly inhibit thrombin, it reduces the conversion of prothrombin to
thrombin through inhibiting the formation of factor Xa by the tissue
factor-activated factor VII complex [5]. Therefore, TFPI2 is also involved
in the regulation of coagulation and ﬁbrinolysis. Taken together, these
ﬁndings suggest that TFPI2 could play a role in the development andprogression of atherosclerotic lesions. In this respect, Crawley et al.
demonstrated increased TFPI2 expression in human atherosclerotic
coronary arteries comparedwith healthy vessels [6], while in advanced
atherosclerotic plaques TFPI2 expression was reduced [7]. In addition,
TFPI2 upregulation has been reported in vascular cells (endothelial cells,
smooth muscle cells) in response to several atherosclerosis-related
stimuli, such as inﬂammatory mediators [8], vascular endothelial
growth factor [9] or shear stress [10]. In these studies, the increase in
TFPI2 expression has been related to the inhibition of EC and SMC
proliferation, indicating that TFPI2 plays a beneﬁcial antiangiogenic and
antiatherogenic role, and contributes to the control of cellular turnover
after vascular injury. However, the regulation of TFPI2 expression in
macrophages, key cells in atherosclerosis development, has not been
studied.
In a previous study using cDNA microarrays, we identiﬁed TFPI2 as
themost differentially expressed gene inmonocytes from patients with
familial combined hyperlipidemia (FCH) compared to healthy controls
[11]. The expression of other related genes (TFPI1 or tissue factor) was
not altered in these samples. The objective of the present study was to
determine the expression of TFPI2 in human THP-1 macrophages after
stimulationwith proatherogenic and proinﬂammatory stimuli, focusing
on the mechanisms involved in the upregulation of this gene caused by
thrombin exposure.
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Cell culture reagents were obtained from Gibco, Invitrogen
Corporation (Paisley, UK), with the exception of fetal bovine serum
(PAA Laboratories, Pasching, Austria), 4-beta phorbol 12-beta myr-
istate 13-alpha acetate (PMA) and human AB serum, which were
purchased from Sigma-Aldrich (St. Louis, MO). Thrombin, lipopoly-
saccharide (Escherichia coli 0127:B8), U0126, PD98059, SP600125,
parthenolide and 3-isobutyl-1-methylxantine (IBMX) were also from
Sigma-Aldrich (St. Louis, MO). Hirudin was purchased from BioPur AG
(Bubendorf, Switzerland), and PPACK and AG1478 were from
Calbiochem (Merck KGaA, Darmstadt, Germany). Trizol reagent was
from Invitrogen Corporation (Paisley, UK). Antibodies were obtained
from Cell Signaling (Danvers, MA), except antibody against total IκBα,
which was from Santa Cruz Biotechnologies (Santa Cruz, CA) and
against TFPI2 (from Abcam, Cambridge, MA). Other general chemicals
were obtained from commercial sources and were of analytical grade.
2.1. Lipoproteins
Very low density lipoproteins (VLDL) were prepared from pooled
plasma samples obtained from anonymous healthy donors (Hospital
Clínic, Barcelona) by sequential ultracentrifugation as previously
described [12]. Lipoproteins were dialyzed against phosphate saline
buffer at 4 °C in the darkness, and their protein concentration was
assessed by themethod of Bradford [13], using bovine serumalbumin as
a standard. Lipoproteins were tested for possible endotoxin contami-
nation using a LAL kit (GenScript), stored at 4 °C and used within
15 days after preparation.
2.2. THP-1 macrophages
THP-1 cells were obtained from the European Collection of Cell
Cultures (ECACC), and maintained in RPMI 1640 medium (with
25 mM Hepes Buffer, supplemented with 10% fetal bovine serum, 1%
L-glutamine 200 mM, 100 U/ml penicillin and 100 μg/ml streptomycin)
at 37 °C in 5% CO2. Differentiation of monocytes to macrophages was
achieved by exposing the cells to 50 ng/ml PMA for 24 h.
2.3. Isolation and culture of peripheral blood mononuclear cells derived
macrophages
Buffy coat preparations were obtained from the Banc de Sang i
Teixits after approval by the Ethical Comitee of Clinical Investigation
(CEIC) of Vall d'Hebron Universitary Hospital (Barcelona). 4 ml of buffy
coat was diluted with 5 ml of PBS, layered onto 6 ml of Ficoll and
peripheral blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation. Mononuclear cells were resuspended in RPMI
medium (supplemented with 1% heat inactivated human AB serum, 1%
L-glutamine 200 mM, 2% sodium pyruvate, 1% non essential fatty acids,
100 U/ml penicillin and 100 μg/ml streptomycin), plated in tissue
culture dishes and placed in a 37 °C incubator for 2 h to allow adherence
to take place [11]. Nonadherent cells were removed by washing with
PBS, and adherentmonocyteswere incubated for 24 h in complete RPMI
mediumwith 10%heat inactivatedhuman serum.After 24 h,monocytes
were washed with PBS and medium was replaced by macrophage–
serum free medium (Invitrogen Corp, CA) with 100 U/ml penicillin
100 μg/ml streptomycin and 2 mM L-glutamine. Cells were cultured for
8 days with fresh addition of media every 3 days until complete
differentiation to macrophages was achieved.
2.4. Cell treatments
Macrophageswere thenwashed three timeswith PBS and incubated
for 24 h with VLDL (0–150 μg/ml), or with thrombin at the usual
concentration range used in macrophages (0–10 U/ml) [14,15]. For theexperiments involving chemical inhibitors, theywere disolved in DMSO
and used to pretreat the cells for 30 min followed by thrombin
stimulation. Controls were pretreated with DMSO for 30 min. The
concentrations of inhibitors used in the present study did not affect cell
viability as evaluated by MTT assay.2.5. RNA extraction, cDNA synthesis and TaqMan real-time PCR
Total RNA was extracted using the Trizol reagent. RNA quantity was
assessed by Nanodrop, and cDNA was synthesized by mixing 0.5 μg of
total RNA, 125 ng of random hexamers in the presence of 75 mM KCl,
3 mM MgCl2, 10 mM dithiothreitol, 200 U Moloney murine leukemia
virus reverse transcriptase, 20 U RNAsin, 0.5 mMof each dNTP (Sigma),
and 50 mM Tris-HCl buffer (pH 8.3). Samples were incubated at 37 °C
for 60 min. Quantitative Taqman PCR was performed with ABI Prism
7700 sequence detector, according to the manufacturer's instructions.
Reactions (20 μl) containing 9 μl of cDNA, primer/probe pairs for TFPI2
(Hs00197918_m1), obtained from Assay-on-demandTM (Applied Bio-
systems, Foster City, USA) and TaqMan Universal PCR Master Mix
solution (Applied Biosystems, Foster City, USA),were run in duplicate. A
threshold cycle value (Ct) was obtained for each ampliﬁcation plot. As
an internal control, primers for glyceraldehyde-3-phosphate dehydro-
genase, GAPDH (Hs99999905_m1) were ampliﬁed in parallel with the
genes of interest. Sequence detector software (S.D.S. 1.9.1) was used for
data analysis. After normalization of Ct values to the reference gene
GAPDH, the relative expression ratio for each gene was calculated from
ΔCt values (based on the difference between themean Ct of the sample
and the corresponding control) and converted to linear expression
values by the formula 2-ΔCt.2.6. Western blot analysis
Protein extracts (40 μg) from control and treated cells were
subjected to 10 % SDS-polyacrylamide gel electrophoresis. Proteins
were then transferred to Immobilon polyvinylidene diﬂuoride transfer
membranes (Millipore, Bedford, MA). In some experiments, superna-
tants from THP-1 macrophages cultured with or without thrombin and
concentrated using Amicon Ultra 10K ﬁlter units (Millipore) were used.
Themembraneswereblocked for 1 h at room temperature in phosphate
saline buffer containing 0.1% Tween 20 (PBST) in the presence of 5%
bovine serum albumin (BSA) and immunological detection was
performed using a primary rabbit polyclonal antibody raised against
P-ERK (dilution 1:1,000), total ERK (dilution 1:1,000), P-JNK (dilution
1:500), total JNK (dilution 1:1,000), P-IκBα (dilution 1:1,000), total
IκBα (dilution 1:200) or TFPI2 (dilution 1:350). After several washes,
blots were incubated with an appropriate secondary antibody, and
detection was achieved using the enhanced chemiluminescence (ECL)
detection system (Amersham Bioscience). Blots were also incubated
with a monoclonal antibody raised against β-actin used as a control of
equal protein loading. Size of detected proteins was estimated using
protein molecular-mass standards (Invitrogen). Chemoluminescence
was detected using a Chemidoc XRS (BioRad), and densitometric
analysis was performed by Quantity One® software. Each band was
quantiﬁed andnormalized toβ-actin signal. Protein levels are expressed
as percentage of controls (100%).2.7. Statistical analysis
Data are presented as mean±standard deviation. An analysis of
variance (ANOVA), combined with a posteriori test, was used to
evaluate the statistical signiﬁcance of the differences. The computer
program GraphPad Instat was used for the calculations, and values of
pb0.05 were considered to be signiﬁcant.
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3.1. Divergent effects of lipoproteins and thrombin on TFPI2 expression
The change inTFPI2expressionobserved inmonocytes fromsubjects
suffering FCH could be a cellular response to the chronic exposure of the
cells to a proatherogenic, proinﬂammatory or prothrombotic environ-
ment [11]. As FCH is thought to be caused primarily by VLDL
overproduction [16], we ﬁrst determined TFPI2 expression in human
THP-1 macrophages treated with these lipoproteins. As shown in
Fig. 1A, the expression of TFPI2 was not altered after treatment of
macrophages with VLDL (0–150 μg/ml). Next, we determined the effect
of thrombin, as it has been reported that thrombin induces the
expression of this gene in hepatic cells [17]. Our results show that
thrombin induced TFPI2 mRNA levels in THP-1 macrophages in a dose
dependent manner, reaching statistical signiﬁcance at 5 U/ml and
maximal effect (1.9-fold increase, pb0.001) at a dose of 10 U/ml
(Fig. 1B). The increase could be observed after 24 h but not after short
periods (4 h) of incubation with this concentration of thrombinA
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Fig. 1. Effects of VLDL and thrombin on TFPI2 mRNA. THP-1 macrophages were incubated w
10 U/ml of thrombin for 4 and 24 h (C), and the mRNA levels of TFPI2 were evaluated by real-
not to thrombin (10 U/ml, 24 h). Arrows indicate three different glycosylated forms of
preincubation with the thrombin inhibitors hirudin (10 U/ml) and PPACK (1 μM) on thromb
TFPI2 expression in human monocyte-derived macrophages. Data were normalized by G
performed in duplicate. (**pb0.01, ***pb0.001 vs control; ###pb0.001 vs thrombin).(Fig. 1C). Consistent with the increase in mRNA levels, western blot
analysis showed increased TFPI2 protein expression in THP-1 macro-
phages treated with 10 U/ml thrombin for 24 h (Fig 1D).
To conﬁrm that TFPI2 induction was thrombin-speciﬁc, we incubat-
ed the cells with the thrombin inhibitors hirudin (10 U/ml) and PPACK
(1 μM) before adding thrombin. Our results show that both agents
prevented the inductive effect of thrombin on TFPI2 while by
themselves they did not exert any effect on TFPI2 expression (Fig. 1E).
To further evaluate physiological relevance, results were conﬁrmed
in humanmonocyte-derivedmacrophages. Consistentwith theﬁndings
in THP-1 macrophages, treatment of human monocyte-derived macro-
phages with thrombin (10 U/ml) for 24 h increased TFPI2 mRNA levels
2.3-fold (pb0.05) (Fig. 1F).
3.2. MAPK inhibitors, but not an EGF receptor antagonist, prevent
thrombin-related TFPI2 mRNA increase
In order to determine the signaling pathways involved in TFPI2
upregulation by thrombin, we pretreated THP-1 macrophages withB
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inhibitor, PD98059, which preferentially inhibits MEK1, and SP600125,
an inhibitor of JNK. As shown in Fig. 2A, all these agents prevented the
thrombin-induced rise in TFPI2 mRNA expression, while preincubation
with the EGF receptor antagonist AG1478 did not affect thrombin-
induced TFPI2 expression.
To conﬁrm that the effect of thrombin on TFPI2 expression is
mediated by the MAPK pathways, we examined the phosphorylation
of ERK and JNK after treatment of macrophages with thrombin, using
western blot analysis. Our results show that both kinases are activated
by thrombin in a time-dependent manner, with maximal effects
observed at 15–30 min (Fig. 2B and C).3.3. NF-κB but not AP-1 pathway is involved in thrombin induced TFPI2
expression
It has been reported that thrombin activates NFκB andAP-1 in THP-1
macrophages [15]. Therefore, we tested whether the induction of TFPI2
by thrombin in these cellswasmediated through the activation of any of
these transcription factors by using parthenolide, an inhibitor of NFκB
[18] or SR-11302, a selective AP-1 inhibitor [19]. In the presence of
parthenolide, but not of SR-11302, the thrombin-mediated induction of
TFPI2 was blunted (Fig. 3A). This demonstrates that thrombin increasesA
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Fig. 2. ERK1/2 and JNK inhibitors, but not an EGFR antagonist, prevent TFPI2 induction by thro
alone or combined with U0126 (10 μM) PD98059 (50 μM), SP600125 (10 μM), or AG1478 (0
were evaluated by real-time PCR, and data were normalized by GAPDH mRNA levels. Graph
(*pb0.05 vs control; #pb0.05 and ###pb0.001 vs thrombin). (B and C) Phosphorylation of ERK
indicated. Equal amounts of total protein (40 μg) were resolved, electrotransferred, and pr
Graphs represent the mean±S.E.M of three independent experiments performed in triplicaTFPI2 mRNA levels through a mechanism involving NF-κB activation.
Using immunoblot analysis we also show here that thrombin increases
IκBα phosphorylation at 15 min, and phosphorylated IκBα levels
remain high up to 60 min after treatment (Fig. 3B).3.4. Treatment with a COX-2 inhibitor enhances the effect of thrombin on
TFPI2 mRNA levels
In hepatic cells, TFPI2 induction by thrombin was COX-2-
dependent [17]. Therefore, we ﬁrst determined whether thrombin
could stimulate COX-2 expression in THP-1 macrophages. Our results
(Fig. 4A) indicate that thrombin upregulated COX-2 mRNA, an
inductive effect that was prevented by ERK1/2 and JNK inhibitors,
similar to TFPI2 induction. In addition, COX-2mRNA increase was also
prevented by preincubation with the EGF receptor antagonist
AG1478. Moreover, COX-2 expression was also induced by thrombin
in human monocyte-derived macrophages (Fig. 4B). In order to
determine whether TFPI2 induction by thrombin was mediated by
COX-2, we treated the cells with a COX-2 inhibitor (NS-398). Our
results showed that this compound increased TFPI2 expression by 2-
fold (pb0.001), an effect that was cumulative to that of thrombin,
resulting in a 3-fold induction when both agents were present
(pb0.001 vs thrombin or NS-398 alone, Fig. 4C). Adding prostaglandinC
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effect of NS-398 on TFPI2 expression (4.8-fold increase pb0.001 vs
NS-398, Fig. 4C). Moreover, treatment with prostaglandin E2 or with
the cAMP-raising agent IBMX also induced TFPI2 expression (4-fold
and 2-fold, respectively, pb0.001, Fig. 4D–E).4. Discussion
TFPI2 may play an important role in atherosclerosis development
[6,7]. Here,wedemonstrate that thrombinupregulates TFPI2 expression
in macrophages by a mechanism involving the MAP kinases ERK and
JNK, linked to NFκB activation.
Previous results obtained by our research group indicates that TFPI2
could be one of the genes regulated by high lipoprotein levels, as its
mRNA expression was markedly increased in monocytes from patients
with FCH [11]. Overproduction and increased plasma VLDL levels are
one of the main characteristics of FCH, but our results showed that
treatment of THP-1 macrophages with increasing concentrations of
VLDL did not induce TFPI2 expression. It iswidely recognized that FCH is
characterized not only by an atherogenic lipoprotein proﬁle, but also bylow-grade inﬂammation [20] and a prothrombotic phenotype [21].
Thrombin exerts powerful inﬂammatory effects on vascular cells,
including monocytes and macrophages, and these effects are related
to atherosclerosis development [22]. Moreover, it has been reported
that thrombin induces TFPI2 expression in human liver myoﬁbroblasts
[17]. Therefore, we studied the effects of thrombin on TFPI2 expression
in THP-1 and human monocyte-derived macrophages, showing an
inductive effect. Preincubationwith the thrombin inhibitors PPACK and
hirudin prevented TFPI2 induction in THP-1macrophages, demonstrat-
ing that the effect was thrombin-speciﬁc and not attributable to LPS
impurities [23].
ERK1/2 activation is one of the most common events in thrombin
signaling in vascular cells, and it is involved in thrombin-induced COX-2
expression inmurinemacrophages [24]. In human livermyoﬁbroblasts,
TFPI2 upregulation is also ERK1/2-dependent, but independent of EGF
receptor [17]. Our results also show that thrombin-induced TFPI2
expression involves the ERK1/2 pathway, as the induction was
prevented by both U0126 and PD98059, and phosphorylation of these
kinases was increased by thrombin treatment. Although transactivation
of EGFRhas been reportedas a commonevent in thrombin signaling, our
results showed thatblocking this receptor did not affect TFPI2 induction.
In contrast, COX-2 expressionwas inducedby thrombin in ourmodel by
a mechanism that is dependent on EGFR transactivation.
Thrombin-mediated induction of TFPI2 is not only dependent on
ERK1/2, but also on JNK activity, as the effect is prevented by
preincubation with SP600125. Moreover, we observed that thrombin
induced JNK phosphorylation after 15–30 min. Although the ERK1/2
and JNK pathways are essential for the activation of the transcription
factor AP-1 [25], the three AP-1 binding sites identiﬁed in the TFPI2
promoter are involved in thenegative control, butnot in the inductionof
TFPI2 gene expression [26]. In consequence, inhibition of AP-1 by SR-
11302 did not affect TFPI2 induction by thrombin. In contrast, the
binding sites for the transcription factorNF-κB present in the TFPI2 gene
promoter are crucial for its induction [26]. Accordingly, we observed
that preincubationwith theNF-κB inhibitor parthenolide prevented the
increase in TFPI2 expression. In support of NF-κB involvement, we
observed that thrombin induced IκB phosphorylation in THP-1
macrophages, an effect that has already been reported in a murine
macrophage cell line [14]. IκB may be phosphorylated by IκB kinase,
which is activated in turn by a number of kinases, including ERK1 [27].
Taken together, our results suggest that thrombin induces TFPI2
expression through ERK1/2 and JNK phosphorylation linked to NFκB
activation, independently of EGF receptor transactivation.
Since in hepatic myoﬁbroblasts thrombin-induced TFPI2 expression
is also mediated through COX-2 [17], we decided to explore the
involvement of this pathway in ourmodel. In our case, pre-incubation of
macrophageswith the selective COX-2 inhibitor NS-398 did not prevent
the inductive effect of thrombin on TFPI2 expression, suggesting that it
was COX-2 independent. In fact, NS-398 itself upregulated TFPI2
expression by a mechanism that was COX-2 independent, as the
induction was not reverted, but rather potentiated, by adding PGE2 to
the cells. PGE2 may modulate gene expression through Gs proteins and
cAMP induction [28]. Interestingly, the increase in cAMP production
causedbyPGE2 is potentiatedbyNS-398 in renal cells [29], andaparallel
increase in cAMP and TFPI2 levels after PGE2 treatment has been
described in endometrial stromal cells [30]. cAMP has been shown to be
involved in thrombin signaling in vascular cells [31], and our results
indicate that treatment of THP-1 macrophages with IBMX, which raises
intracellular cAMP by inhibiting phosphodiesterases, induces TFPI2
expression to a similar degree as thrombin. Therefore, we could
speculate that thrombin may induce TFPI2 in macrophages by a
cAMP-related mechanism, and NS-398 would potentiate this effect.
The consequences of TFPI2 induction in macrophages may affect the
development of the lesion itself, either by effects on the extracellular
matrix or on surrounding cells. As previously commented, most of these
effects are considered as anti-atherogenic. For example, one of themajor
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Fig. 4. (A) Thrombin induces COX-2 expression in THP1 macrophages. Analysis of COX-2 mRNA levels in THP-1 macrophages incubated with thrombin alone or combined with
U0126 (10 μM) PD98059 (50 μM), SP600125 (10 μM), or AG1478 (0.5 μM) for 24 h. The inhibitors were added 30 min before thrombin. COX-2 mRNA levels were evaluated by real-
time PCR, and data were normalized by GAPDHmRNA levels. The graph represents the mean±S.E.M of six independent experiments performed in duplicate (***pb0.001 vs control,
### pb0.001 vs thrombin). (B) Effect of treatment with thrombin (10 U/ml, 24 h) on COX-2 expression in humanmonocyte-derived macropahges. (C, D) Effects of a COX-2 inhibitor
and PGE2 on thrombin-induced TFPI2 expression. Analysis of TFPI2 mRNA levels in THP-1 macrophages incubated with thrombin, NS-398 (5 μM), PGE2 (1 μM) or combinations. (E)
Effects of IBMX treatment on TFPI2 expression. TFPI2 mRNA levels were evaluated by real-time PCR, and data were normalized by GAPDH mRNA levels. The graph represent the
mean±S.E.M of six independent experiments performed in duplicate (*pb0.05 and ***pb0.001 vs control, ### pb0.001 vs thrombin).
1259J. Pou et al. / Biochimica et Biophysica Acta 1813 (2011) 1254–1260roles of TFPI-2 in vivo is plasmin andMMPs inhibition,whichmay inhibit
ECM degradation and increase atherosclerotic plaque stability [6]. Very
recently, it has been proposed that TFPI2 may also play an antiathero-
genic role by promoting macrophage apoptosis [32]. Therefore, the
induction of TFPI2 expression by thrombin could represent a physiolog-
ical negative feedback regulatory mechanism triggered to avoid
excessive MMP activity and limit lesion cellularity in atherosclerotic
lesions. Further studies are required to unravel the relationship between
TFPI2 and thrombin in the context of atherosclerosis progression.
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